Journal of Korean Diabetes,
Год журнала:
2023,
Номер
24(3), С. 111 - 119
Опубликована: Сен. 30, 2023
Most
patients
with
diabetes
mellitus
(DM)
have
dyslipidemia,
which
is
characterized
by
increased
triglycerides,
decreased
high-density
lipoprotein
cholesterol,
and
small
dense
low-density
cholesterol
(LDL-C).
Dyslipidemia
an
important
modifiable
risk
factor
for
cardiovascular
disease
(CVD).
Therefore
active
management
essential.
Despite
its
increasing
prevalence,
the
proportion
of
adequately-controlled
dyslipidemia
small,
efforts
to
improve
this
pattern
are
required.
The
Korean
Diabetes
Association
guidelines
recommend
setting
goals
evaluating
each
patient’s
future
CVD
risk,
including
presence
or
absence
CVD,
target
organ
damage,
major
factors,
duration
DM.
primary
LDL-C
level
below
55
mg/dL
(and
a
reduction
in
50%
more
from
baseline),
70
mg/dL,
100
highest
group
lowest
group,
respectively.
Statins
first-line
drug
choice,
if
not
reached
maximum
tolerable
dose
statin,
combination
therapy
ezetimibe
proprotein
convertase
subtilisin/kexin
type
9
inhibitors
recommended.
In
hypertriglyceridemia,
lifestyle
changes
weight
loss
abstinence
alcohol
very
important,
along
glycemic
control.
Diabetes & Metabolism Journal,
Год журнала:
2023,
Номер
47(5), С. 575 - 594
Опубликована: Сен. 26, 2023
In
May
2023,
the
Committee
of
Clinical
Practice
Guidelines
Korean
Diabetes
Association
published
revised
clinical
practice
guidelines
for
adults
with
diabetes
and
prediabetes.
We
incorporated
latest
research
findings
through
a
comprehensive
systematic
literature
review
applied
them
in
manner
suitable
population.
These
are
designed
all
healthcare
providers
nationwide,
including
physicians,
experts,
certified
educators
who
manage
patients
or
individuals
at
risk
developing
diabetes.
Based
on
recent
changes
international
results
epidemiological
study,
recommended
age
screening
has
been
lowered.
collaboration
relevant
medical
societies,
recently
managing
hypertension
dyslipidemia
have
into
this
guideline.
An
abridgment
containing
practical
information
patient
education
management
clinic
was
separately.
Journal of Lipid and Atherosclerosis,
Год журнала:
2023,
Номер
12(3), С. 237 - 237
Опубликована: Янв. 1, 2023
This
study
aimed
to
investigate
the
prevalence
and
status
of
dyslipidemia
management
among
South
Korean
adults,
as
performed
by
Society
Lipid
Atherosclerosis
under
name
Dyslipidemia
Fact
Sheet
2022.We
analyzed
lipid
profiles,
age-standardized
crude
prevalence,
hypercholesterolemia
dyslipidemia,
health
behaviors
adults
aged
≥20
years,
using
Korea
National
Health
Nutrition
Examination
Survey
data
between
2007
2020.In
Korea,
(total
cholesterol
≥240
mg/dL
or
use
a
lipid-lowering
drug)
in
2020
was
24%,
more
than
doubled
from
2020.
The
treatment
rate
55.2%,
control
47.7%.
(more
one
out
three
conditions
[low-density
lipoprotein-cholesterol
≥160
drug,
triglycerides
≥200,
high-density
(men
women)
<40
mg/dL])
40.2%
2016
However,
it
increased
48.2%
when
definition
hypo-high-density
lipoprotein-cholesterolemia
women
changed
<50
mg/dL.Although
has
steadily
remains
low.
Therefore,
continuous
efforts
are
needed
manage
through
cooperation
national
healthcare
system,
patients,
providers.
Diabetes & Metabolism Journal,
Год журнала:
2023,
Номер
47(5), С. 632 - 642
Опубликована: Авг. 2, 2023
This
study
aimed
to
investigate
the
prevalence
and
status
of
dyslipidemia
management
among
South
Korean
adults,
as
performed
by
Society
Lipid
Atherosclerosis
under
name
Dyslipidemia
Fact
Sheet
2022.
Diabetes & Metabolism Journal,
Год журнала:
2024,
Номер
48(2), С. 184 - 195
Опубликована: Янв. 26, 2024
Hypertriglyceridemia
and
decreased
high-density
lipoprotein
cholesterol
(HDL-C)
persist
despite
statin
therapy,
contributing
to
residual
atherosclerotic
cardiovascular
disease
(ASCVD)
risk.
Asian
subjects
are
metabolically
more
susceptible
hypertriglyceridemia
than
other
ethnicities.
Fenofibrate
regulates
hypertriglyceridemia,
raises
HDL-C
levels,
is
a
recommended
treatment
for
dyslipidemia.
However,
data
on
fenofibrate
use
across
different
regions
limited.
This
narrative
review
summarizes
the
efficacy
safety
of
in
with
dyslipidemia
related
comorbidities
(diabetes,
metabolic
syndrome,
diabetic
retinopathy,
nephropathy).
Long-term
resulted
fewer
(CV)
events
reduced
composite
heart
failure
hospitalizations
or
CV
mortality
type
2
diabetes
mellitus.
plays
significant
role
improving
irisin
resistance
microalbuminuria,
inhibiting
inflammatory
responses,
reducing
retinopathy
incidence.
plus
combination
significantly
risk
patients
syndrome
demonstrated
triglyceride
increased
levels
an
acceptable
profile
those
high
ASCVD
Nevertheless,
care
necessary
due
possible
hepatic
renal
toxicities
vulnerable
individuals.
trials
real-world
studies
needed
confirm
clinical
benefits
heterogeneous
population
Journal of Korean Diabetes,
Год журнала:
2023,
Номер
24(3), С. 120 - 126
Опубликована: Сен. 30, 2023
The
Committee
on
Clinical
Practice
Guidelines
of
the
Korean
Diabetes
Association
updated
previous
clinical
practice
guidelines
for
adults
with
diabetes
and
prediabetes
published
eighth
edition
in
May
2023.
We
performed
a
comprehensive
systematic
review
recent
trials
evidence
suitable
population
that
could
be
applicable
to
real-world
practice.
These
were
developed
enable
all
healthcare
providers
including
physicians,
experts,
certified
educators
nationwide
best
care
individuals
setting.
recommendations
screening,
medical
nutrition
therapy,
pharmacologic
therapy
type
2
diabetes,
obesity,
hypertension,
lipid
management
revised
updated.
use
real-time
continuous
glucose
monitoring
(CGM)
devices
was
recommended
1
treated
multiple
insulin
injections,
additional
CGM
metrics
added
blood
control
target.
Cardiovascular Diabetology,
Год журнала:
2024,
Номер
23(1)
Опубликована: Июль 18, 2024
Abstract
Background
The
beneficial
effects
of
fenofibrate
on
atherosclerotic
cardiovascular
disease
(ASCVD)
outcomes
in
patients
with
diabetes
and
statin
treatment
are
unclear.
We
investigated
the
all-cause
mortality
ASCVD
diabetes,
high
triglyceride
(TG)
levels
treatment.
Methods
performed
a
nationwide
propensity-score
matched
(1:1)
cohort
study
using
data
from
National
Health
Information
Database
Republic
Korea
2010
to
2017.
included
110,723
individuals
TG
≥
150
mg/dL,
no
prior
diagnoses
who
used
statins
fenofibrate,
an
equal
number
similar
alone
(control
group).
newly
diagnosed
myocardial
infarction
(MI),
stroke,
both
(MI
and/or
stroke),
mortality.
Results
Over
mean
4.03-year
follow-up
period,
hazard
ratios
(HR)
for
group
comparison
control
were
0.878
[95%
confidence
interval
(CI)
0.827–0.933]
MI,
0.901
(95%
CI
0.848–0.957)
0.897
0.858–0.937)
MI
0.716
0.685–0.749)
death.
These
consistent
subgroup
150–199
mg/dL
but
differed
according
low-density
lipoprotein
cholesterol
(LDL-C)
levels.
Conclusion
In
this
involving
risk
death
was
significantly
lower
use
conjunction
compared
alone.
However,
finding
significant
only
relatively
LDL-C
Graphical
JACC Asia,
Год журнала:
2025,
Номер
5(3), С. 333 - 349
Опубликована: Март 1, 2025
The
management
of
atherosclerotic
cardiovascular
disease
(ASCVD)
in
the
United
States
is
currently
based
upon
large
epidemiological
studies
primarily
non-Hispanic
White
subjects.
Although
this
strategy
provides
a
uniform
approach
that
simpler
to
implement,
it
may
result
inappropriately
targeting
certain
Asian
populations
for
treatment
on
inaccurate
ASCVD
risk
estimation.
In
state-of-the-art
review,
we
detail
similarities
and
differences
prevalence
its
factors
among
Chinese,
Japanese,
Korean
people
living
their
native
countries.
We
highlight
limitations
current
calculators
when
applied
East
immigrants
summarize
stratification
approaches
China,
Japan,
Korea.
Our
review
underscores
need
disaggregate
registry,
cohort,
clinical
trial
data
by
subgroups,
actively
engage
these
research,
initiate
better
define
States.
Cardiovascular Diabetology,
Год журнала:
2024,
Номер
23(1)
Опубликована: Сен. 3, 2024
Abstract
Background
The
potential
preventive
effect
of
fenofibrate
on
lower
extremity
amputation
(LEA)
and
peripheral
arterial
disease
(PAD)
in
patients
with
type
2
diabetes
(T2D)
is
not
fully
elucidated.
Methods
We
selected
adult
≥
20
years
age
T2D
from
the
Korean
National
Health
Insurance
Service
Database
(2009–2012).
users
were
matched
a
1:4
ratio
non-users
using
propensity
scores
(PS).
outcome
variables
composite
LEA
PAD
individual
components.
risks
outcomes
implemented
as
hazard
(HR)
95%
confidence
intervals
(CI).
For
safety
issues,
acute
kidney
injury,
rhabdomyolysis
resulting
hospitalization
analyzed.
Results
A
total
114,920
was
included
analysis
median
follow-up
duration
7.6
(22,984
91,936
for
user
non-user
groups,
respectively).
After
PS
matching,
both
groups
well
balanced.
group
associated
significantly
(HR
0.81;
CI
0.70–0.94),
0.76;
0.60–0.96),
0.68–0.96).
risk
rhabdomyolysis,
or
these
events
showed
no
significant
difference
between
two
groups.
Subgroup
analyses
revealed
consistent
benefits
across
genders,
baseline
lipid
profiles.
Conclusions
This
nationwide
population-based
retrospective
observational
study
suggests
that
can
prevent
who
are
statin
therapy.
European Heart Journal - Cardiovascular Pharmacotherapy,
Год журнала:
2023,
Номер
10(2), С. 118 - 127
Опубликована: Ноя. 28, 2023
Omega-3
fatty
acids
and
fenofibrates
have
shown
some
beneficial
cardiovascular
effects;
however,
their
efficacy
has
not
been
compared.
This
study
aimed
to
compare
the
effectiveness
of
currently
available
omega-3
fenofibrate
for
reducing
major
adverse
events
(MACE).
From
a
nationwide
population-based
cohort
in
South
Korea
(2008-2019),
individuals
with
metabolic
syndrome
(≥30
years)
who
received
statin
those
receiving
were
matched
by
propensity
score
(n
=
39
165
both
groups).
The
primary
outcome
was
MACE,
including
ischaemic
heart
disease
(IHD),
stroke
(IS),
death
from
causes.
risk
MACE
lower
[hazard
ratio
(HR),
0.79;
95%
confidence
interval
(CI),
0.74-0.83]
group
than
acid
group.
Fenofibrate
associated
incidence
IHD
(HR,
0.72;
CI,
0.67-0.77)
hospitalization
failure
0.90;
0.82-0.97),
but
IS
0.81-1.00)
nor
causes
1.07;
0.97-1.17).
effect
compared
prominent
patients
preexisting
atherosclerotic
doses
(≤2
g
per
day).
In
real-world
setting,
use
low-dose
when
added
statins
people
syndrome.
